Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
VALENCIA, Calif., Aug. 25, 2016 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced that the United States District Court for the Central District of California has dismissed the class action that was pending against MannKind Corporation and two of its executives. The Court granted the defendants’ motion to dismiss the plaintiffs’ amended class action complaint without leave to amend, thereby closing the case. The plaintiffs can appeal the decision within 30 days.
ABOUT MANNKIND CORPORATION
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Rose Alinaya SVP, Finance 661-775-5300 [email protected]
